托法替尼中间体; 4-氯吡咯并[2,3-d]嘧啶; 托法替尼 intB1; 6-氯-7-脱氮嘌呤; 6-氯-7-氮杂嘌呤; 4-氯-7H-吡咯[2,3-d]嘧啶; 4-氯-7H-吡咯[2,3-D]嘧啶; 4-氯-7H-吡咯并[2,3-d]嘧啶; 4-氯吡咯[2,3-d]嘧啶; 4-氯-7-氢-吡咯-[2,3-d]嘧啶; 4-氯吡咯并嘧啶; 4-氯-5-H-吡咯[3,2-d]并嘧啶; 4-氯-5H-吡咯并[3,2-d]嘧啶; 4-氯-5氢吡咯[3,2-d]嘧啶; 6-氯-7-脱氮嘌呤; 6-氯-7-氮杂嘌呤; 4-氯吡咯[2,3-d]嘧啶; 4-氯-7-氢-吡咯-[2,3-d]嘧啶; 4-氯吡咯并嘧啶; 4-氯-5-H-吡咯[3,2-d]并嘧啶; 4-氯-5H-吡咯并[3,2-d]嘧啶; 4-氯-5氢吡咯[3,2-d]嘧啶; 4-氯-7H-吡咯[2,3-d]嘧啶
6-Chloro-7-deazapurine; 4-Chloropyrrolo[2,3-d]Pyrimidine; MFCD01686865; 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine; 4-Chlor-7H-pyrrolo[2,3-d]pyrimidin; 4-Chloro-1H-pyrrolo(2,3-d)pyrimidine; Tofacitinib Impurity Q; 4-Chloro-1H-pyrrolo[2,3-d]pyrimidine; 4-chloro-7H-pyrrolo[2,3-d]pyrimidine; 4-methyl-1,3-thiazole-2,5-diamine; 4-chloro-7H-pyrollo(2,3-D)pyrimidine; 7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-; 5H-Pyrrolo[3,2-d]pyrimidine, 4-Chloro-; 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine; 4-Chloro-5H-pyrrolo[3,2-D] pyrimidine; 4-Chloro-5H-pyrrol[3,2-d] pyrimidine; Chloro-5H-pyrrol[3,2-d]pyrimidine, 4-; 4-chloropyrrolo(2,3-d)pyrimidine
常温,避光,通风干燥处,密封保存
1.疏水参数计算参考值(XlogP):1.6 2.氢键供体数量:1 3.氢键受体数量:2 4.可旋转化学键数量:0 5.互变异构体数量:3 6.拓扑分子极性表面积41.6 7.重原子数量:10 8.表面电荷:0 9.复杂度:130 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1
PDF: 3680-69-1_ch
PDF: 3680-69-1_en